{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:29:09Z","timestamp":1787668149270,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor\u2019s Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard. In the past decade, different models have been proposed aiming at maximizing NK cell activation by activating KIR-ligand interactions or minimizing inhibitory KIR-ligand interactions. Alternative classifications intended predicting outcome after alloHCT by donor KIR-haplotypes. In the present study, we aimed at validating proposed models and exploring more classification approaches. To this end, we analyzed samples stored at the Collaborative Biobank from HLA-compatible unrelated stem cell donors who had donated for patients with acute myeloid leukemia (AML) or myelodysplastic neoplasm (MDS) and whose outcome data had been reported to EBMT or CIBMTR. The donor\n                    <jats:italic>KIR<\/jats:italic>\n                    genotype was determined by high resolution amplicon-based next generation sequencing. We analyzed data from 5,017 transplants. The median patient age at alloHCT was 56 years. Patients were transplanted for AML between 2013 and 2018. Donor-recipient pairs were matched for HLA-A, -B, -C, -DRB1, and -DQB1 (79%) or had single HLA mismatches. Myeloablative conditioning was given to 56% of patients. Fifty-two percent of patients received anti-thymocyte-globulin-based graft-versus-host disease prophylaxis, 32% calcineurin-inhibitor-based prophylaxis, and 7% post-transplant cyclophosphamide-based prophylaxis. We tested several previously reported classifications in multivariable regression analyses but could not confirm outcome associations. Exploratory analyses in 1,939 patients (39%) who were transplanted from donors with homozygous centromeric (cen) or telomeric (tel)\n                    <jats:italic>A<\/jats:italic>\n                    or\n                    <jats:italic>B<\/jats:italic>\n                    motifs, showed that the donor cen\n                    <jats:italic>B\/B<\/jats:italic>\n                    -tel\n                    <jats:italic>A\/A<\/jats:italic>\n                    diplotype was associated with a trend to better event-free survival (HR 0.84, p=.08) and reduced risk of non-relapse mortality (NRM) (HR 0.65, p=.01). When we further dissected the contribution of B subtypes, we found that only the cen\n                    <jats:italic>B01\/B01<\/jats:italic>\n                    -\n                    <jats:italic>telA\/A<\/jats:italic>\n                    diplotype was associated with a reduced risk of relapse (HR 0.40, p=.04) while all subtype combinations contributed to a reduced risk of NRM. This exploratory finding has to be validated in an independent data set. In summary, the existing body of evidence is not (yet) consistent enough to recommend use of donor\n                    <jats:italic>KIR<\/jats:italic>\n                    genotype information for donor selection in routine clinical practice.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2024.1350470","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:46:00Z","timestamp":1712036760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight"],"prefix":"10.3389","volume":"15","author":[{"given":"Johannes","family":"Schetelig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Baldauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorinde D.","family":"Hoogenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Spellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sengeloev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Wagner-Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankara","family":"Paneesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno A. A.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth C.","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzenz","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Tsi","family":"Bolon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G. E.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahinaz M.","family":"Gadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Paczesny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Fleischhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase ii study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid Malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML","volume":"24","author":"Bjorklund","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.804988","article-title":"Long-term outcome after adoptive immunotherapy with natural killer cells: alloreactive NK cell dose still matters","volume":"12","author":"Parisi","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/jci154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0091","article-title":"Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors","volume":"102","author":"Giebel","year":"2003","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4825","article-title":"Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes","volume":"105","author":"Hsu","year":"2005","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065383","article-title":"Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT","volume":"109","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7059","article-title":"KIR3DL1\/Hl a-B Subtypes Govern Acute Myelogenous Leukemia Relapse after Hematopoietic Cell Transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.10.016","article-title":"Killer immunoglobulin-like receptor-ligand interactions predict clinical outcomes following unrelated donor transplantations","volume":"26","author":"Krieger","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01393-9","article-title":"Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for aml","volume":"56","author":"Krieger","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302517","article-title":"Donor killer cell ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia","volume":"192","author":"Cooley","year":"2014","journal-title":"J Immunol"},{"key":"B18","article-title":"The Impact of Donor KIR2DL Allele Combinations on Outcome after Unrelated Donor Transplantation in Patients with Acute Myeloid Leukemia","volume-title":"The 18th meeting of the Society for Natural Immunity","author":"Schetelig","year":""},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002887","article-title":"External validation of models for KIR2DS1\/KIR3DL1-informed selection of hematopoietic cell donors fails","volume":"135","author":"Schetelig","year":"2020","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584520","article-title":"Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"11","author":"Schetelig","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001053","article-title":"KIR B donors improve the outcome for aml patients given reduced intensity conditioning and unrelated donor transplantation","volume":"4","author":"Weisdorf","year":"2020","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02843","article-title":"Allele-level KIR genotyping of more than a million samples: workflow, algorithm, and observations","volume":"9","author":"Wagner","year":"2018","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aao2892","article-title":"Inhibitory killer cell immunoglobulin-like receptors strengthen Cd8(+) T cell-mediated control of HIV-1, HCV, and HTLV-1","volume":"3","author":"Boelen","year":"2018","journal-title":"Sci Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.10.016","article-title":"Killer immunoglobulin-like receptor-ligand interactions predict clinical outcomes following unrelated donor transplantations","volume":"26","author":"Krieger","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011622","article-title":"Systematic evaluation of donor-KIR\/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML","volume":"8","author":"Fein","year":"2024","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015115","article-title":"Different patterns of evolution in the centromeric and telomeric regions of group a and B haplotypes of the human killer cell ig-like receptor locus","volume":"5","author":"Pyo","year":"2010","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1101\/gr.137976.112","article-title":"Copy number variation leads to considerable diversity for B but not a haplotypes of the human KIR genes encoding NK cell receptors","volume":"22","author":"Jiang","year":"2012","journal-title":"Genome Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501358","article-title":"Polymorphic HLA-C receptors balance the functional characteristics of KIR haplotypes","volume":"195","author":"Hilton","year":"2015","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1140","article-title":"Ipd\u2013the immuno polymorphism database","volume":"41","author":"Robinson","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed aml after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0601-7","article-title":"Role of the inhibitory KIR ligand HLA-bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells","volume":"58","author":"Verheyden","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015230","article-title":"Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy","volume":"2","author":"Mastaglio","year":"2018","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00429","article-title":"Estimation of german KIR allele group haplotype frequencies","volume":"11","author":"Solloch","year":"2020","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100119","article-title":"Following transplantation for acute myelogenous leukemia, donor KIR cen B02 better protects against relapse than KIR cen B01","volume":"206","author":"Guethlein","year":"2021","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047491","article-title":"Allele-level haplotype frequencies and pairwise linkage disequilibrium for 14 kir loci in 506 european-american individuals","volume":"7","author":"Vierra-Green","year":"2012","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/gepi.22538","article-title":"Haplotype reconstruction for genetically complex regions with ambiguous genotype calls: illustration by the KIR gene region","volume":"48","author":"van der Burg","year":"2024","journal-title":"Genet Epidemiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00193","article-title":"Canonical and cross-reactive binding of NK cell inhibitory receptors to HLA-C allotypes is dictated by peptides bound to HLA-C","volume":"8","author":"Sim","year":"2017","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-017-1001-y","article-title":"Missing or altered self: human NK cell receptors that recognize HLA-C","volume":"69","author":"Hilton","year":"2017","journal-title":"Immunogenetics"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical hsct with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1350470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:46:05Z","timestamp":1712036765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1350470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2024.1350470"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1350470","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"article-number":"1350470"}}